Definium Therapeutics (DFTX) Net Cash Flow (2019 - 2026)
Definium Therapeutics (DFTX) reported Net Cash Flow of $4.7 million for Q1 2026, up 102.45% year-over-year from $2.3 million in Q1 2025, and down 98.03% on a QoQ basis from $237.9 million in Q4 2025.
Definium Therapeutics (DFTX) has 8 years of Net Cash Flow data on file, last reported at $4.7 million in Q1 2026.
- Quarterly Net Cash Flow rose 102.45% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.7 million (up 206.02% YoY) and the FY2025 annual result came in at -$15.9 million, down 109.13% from the prior year.
- Net Cash Flow declined to $4.7 million in Q1 2026 per DFTX's latest filing, from $237.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $237.9 million in Q4 2025 and bottomed at -$190.9 million in Q1 2025.
- The 5-year median for Net Cash Flow is -$12.6 million (2023), against an average of $7.6 million.
- The widest annual swing landed in 2024, when Net Cash Flow jumped 6656.87%; it then tumbled 437.84% in 2025.
- Tracing DFTX's Net Cash Flow over 5 years: stood at -$12.4 million in 2022, then plunged by 44.53% to -$18.0 million in 2023, then retreated by 19.89% to -$21.5 million in 2024, then surged by 1204.15% to $237.9 million in 2025, then sank by 98.03% to $4.7 million in 2026.
- Per Business Quant, the three latest DFTX Net Cash Flow figures stand at $4.7 million (Q1 2026), $237.9 million (Q4 2025), and -$13.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | 4.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.68 Mn |
| Mar 31, 2026 | 4.68 Mn |
| Dec 31, 2025 | 237.88 Mn |
| Dec 31, 2025 | 237.88 Mn |
| Sep 30, 2025 | -13.41 Mn |
| Sep 30, 2025 | -13.41 Mn |
| Jun 30, 2025 | -49.49 Mn |
| Jun 30, 2025 | -49.49 Mn |
| Mar 31, 2025 | -190.88 Mn |
| Mar 31, 2025 | -190.88 Mn |
| Dec 31, 2024 | -21.54 Mn |
| Dec 31, 2024 | -21.54 Mn |
| Sep 30, 2024 | 52.16 Mn |
| Sep 30, 2024 | 52.16 Mn |
| Jun 30, 2024 | -9.20 Mn |
| Jun 30, 2024 | -9.20 Mn |
| Mar 31, 2024 | 152.65 Mn |
| Mar 31, 2024 | 152.65 Mn |
| Dec 31, 2023 | -17.97 Mn |
| Dec 31, 2023 | -17.97 Mn |
| Sep 30, 2023 | 772,000.00 |
| Sep 30, 2023 | 772,000.00 |
| Jun 30, 2023 | -12.57 Mn |
| Jun 30, 2023 | -12.57 Mn |
| Mar 31, 2023 | -12.75 Mn |
| Mar 31, 2023 | -12.75 Mn |
| Dec 31, 2022 | -12.43 Mn |
| Dec 31, 2022 | -12.43 Mn |
| Sep 30, 2022 | 48.91 Mn |
| Sep 30, 2022 | 48.91 Mn |
| Jun 30, 2022 | -14.54 Mn |
| Jun 30, 2022 | -14.54 Mn |
| Mar 31, 2022 | -13.03 Mn |
| Mar 31, 2022 | -13.03 Mn |
| Dec 31, 2021 | -7.59 Mn |
| Dec 31, 2021 | -7.59 Mn |
| Sep 30, 2021 | -15.99 Mn |
| Sep 30, 2021 | -15.99 Mn |
| Jun 30, 2021 | -3.35 Mn |
| Jun 30, 2021 | -3.35 Mn |
| Mar 31, 2021 | 79.63 Mn |
| Mar 31, 2021 | 79.63 Mn |
| Dec 31, 2020 | 61.57 Mn |
| Dec 31, 2020 | 61.57 Mn |
| Sep 30, 2020 | -5.83 Mn |
| Sep 30, 2020 | -5.83 Mn |
| Jun 30, 2020 | 3.56 Mn |
| Jun 30, 2020 | 3.56 Mn |
| Mar 31, 2020 | 13.81 Mn |
| Mar 31, 2020 | 13.81 Mn |
| Dec 31, 2019 | 6.70 Mn |
| Dec 31, 2019 | 6.70 Mn |